These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22790350)

  • 1. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.
    Minami T; Kishikawa T; Sato M; Tateishi R; Yoshida H; Koike K
    J Gastroenterol; 2013 Feb; 48(2):254-68. PubMed ID: 22790350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
    Druyts E; Thorlund K; Wu P; Kanters S; Yaya S; Cooper CL; Mills EJ
    Clin Infect Dis; 2013 Apr; 56(7):961-7. PubMed ID: 23243171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.
    Witthöft T; Möller B; Wiedmann KH; Mauss S; Link R; Lohmeyer J; Lafrenz M; Gelbmann CM; Hüppe D; Niederau C; Alshuth U
    J Viral Hepat; 2007 Nov; 14(11):788-96. PubMed ID: 17927615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
    Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
    Hauser G; Awad T; Thorlund K; Štimac D; Mabrouk M; Gluud C
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005642. PubMed ID: 24585451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.
    Miyase S; Haraoka K; Ouchida Y; Morishita Y; Fujiyama S
    J Gastroenterol; 2012 Sep; 47(9):1014-21. PubMed ID: 22382633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
    Opravil M; Sasadeusz J; Cooper DA; Rockstroh JK; Clumeck N; Clotet B; Montaner J; Torriani FJ; Depamphilis J; Dieterich DT
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):36-49. PubMed ID: 18156990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.
    Brjalin V; Salupere R; Tallo T; Kuznetsova T; Priimägi L; Tefanova V
    Cent Eur J Public Health; 2012 Jun; 20(2):150-5. PubMed ID: 22966742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
    Kogure T; Ueno Y; Fukushima K; Nagasaki F; Kondo Y; Inoue J; Matsuda Y; Kakazu E; Yamamoto T; Onodera H; Miyazaki Y; Okamoto H; Akahane T; Kobayashi T; Mano Y; Iwasaki T; Ishii M; Shimosegawa T
    World J Gastroenterol; 2008 Dec; 14(47):7225-4230. PubMed ID: 19084938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
    Ueda T; Tsuchiya K; Hashimoto S; Inoue T; Enomoto N; Inao M; Tanaka A; Kaito M; Imazeki F; Nishiguchi S; Mochida S; Yokosuka O; Yatsuhashi H; Izumi N; Kudo M;
    Dig Dis; 2012; 30(6):554-60. PubMed ID: 23258094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    Helal GK; Gad MA; Abd-Ellah MF; Mahgoup EM
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):553-7. PubMed ID: 26872109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
    Ide K; Sato I; Imai T; Hawke P; Yamada H; Kawasaki Y; Masaki N
    Biol Pharm Bull; 2016 Dec; 39(12):2060-2065. PubMed ID: 27645378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
    J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.
    Perrillo R; Rothstein KD; Rubin R; Alam I; Imperial J; Harb G; Hu S; Klaskala W
    J Viral Hepat; 2004 Mar; 11(2):157-65. PubMed ID: 14996351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.